Targeted lipid based drug conjugates: A novel strategy for drug delivery

被引:40
|
作者
Vadlapudi, Aswani Dutt [1 ]
Vadlapatla, Ramya Krishna [1 ]
Kwatra, Deep [2 ]
Earla, Ravinder [1 ]
Samanta, Swapan K. [1 ]
Pal, Dhananjay [1 ]
Mitra, Ashim K. [1 ]
机构
[1] Univ Missouri, Sch Pharm, Div Pharmaceut Sci, Kansas City, MO 64108 USA
[2] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA
关键词
Acyclovir; Targeted lipid prodrugs; Biotin; SMVT; Affinity; Drug delivery; DEPENDENT MULTIVITAMIN TRANSPORTER; L-VALYL ESTER; ACYCLOVIR DIPHOSPHATE DIMYRISTOYLGLYCEROL; POSSIBLE ANTIVIRAL AGENTS; CORNEAL EPITHELIAL-CELLS; AMINO-ACID TRANSPORTER; FUNCTIONAL-CHARACTERIZATION; OLIGOPEPTIDE TRANSPORTER; BIOTIN UPTAKE; DIPEPTIDE PRODRUGS;
D O I
10.1016/j.ijpharm.2012.05.033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A majority of studies involving prodrugs are directed to overcome low bioavailability of the parent drug. The aim of this study is to increase the bioavailability of acyclovir (ACV) by designing a novel prodrug delivery system which is more lipophilic, and at the same time site specific. In this study, a lipid raft has been conjugated to the parent drug molecule to impart lipophilicity. Simultaneously a targeting moiety that can be recognized by a specific transporter/receptor in the cell membrane has also been tethered to the other terminal of lipid raft. Targeted lipid prodrugs i.e., biotin-ricinoleicacid-acyclovir (B-R-ACV) and biotin-12hydroxystearicacid-acyclovir (B-12HS-ACV) were synthesized with ricinoleicacid and 12hydroxystearicacid as the lipophilic rafts and biotin as the targeting moiety. Biotin-ACV (B-ACV), ricinoleicacid-ACV (R-ACV) and 12hydroxystearicacid-ACV (12HS-ACV) were also synthesized to delineate the individual effects of the targeting and the lipid moieties. Cellular accumulation studies were performed in confluent MDCK-MDR1 and Caco-2 cells. The targeted lipid prodrugs B-R-ACV and B-12HS-ACV exhibited much higher cellular accumulation than B-ACV, R-ACV and 12HS-ACV in both cell lines. This result indicates that both the targeting and the lipid moiety act synergistically toward cellular uptake. The biotin conjugated prodrugs caused a decrease in the uptake of [H-3] biotin suggesting the role of sodium dependent multivitamin transporter (SMVT) in uptake. The affinity of these targeted lipid prodrugs toward SMVT was studied in MDCK-MDR1 cells. Both the targeted lipid prodrugs B-R-ACV (20.25 +/- 1.74 mu M) and B-12HS-ACV (23.99 +/- 3.20 mu M) demonstrated higher affinity towards SMVT than B-ACV (30.90 +/- 4.19 mu M). Further, dose dependent studies revealed a concentration dependent inhibitory effect on [H-3] biotin uptake in the presence of biotinylated prodrugs. Transepithelial transport studies showed lowering of [H-3] biotin permeability in the presence of biotin and biotinylated prodrugs, further indicating a carrier mediated translocation by SMVT. Overall, results from these studies clearly suggest that these biotinylated lipid prodrugs of ACV possess enhanced affinity towards SMVT. These prodrugs appear to be potential candidates for the treatment of oral and ocular herpes virus infections, because of higher expression of SMVT on intestinal and corneal epithelial cells. In conclusion we hypothesize that our novel prodrug design strategy may help in higher absorption of hydrophilic parent drug. Moreover, this novel prodrug design can result in higher cell permeability of hydrophilic therapeutics such as genes, siRNA, antisense RNA, DNA, oligonucleotides, peptides and proteins. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:315 / 324
页数:10
相关论文
共 50 条
  • [1] Carbohydrate - lipid conjugates for targeted drug and gene delivery
    Ahmad, Moghis U.
    Ali, Shoukath M.
    Ahmad, Ateeq
    Sheikh, Saifuddin
    Chen, Paul
    Ahmad, Imran
    Lipid Technology, 2015, 27 (10) : 223 - 226
  • [2] Antibody–drug conjugates for targeted anticancer drug delivery
    Kim Y.
    Park E.J.
    Na D.H.
    Journal of Pharmaceutical Investigation, 2016, 46 (4) : 341 - 349
  • [3] Drug–Lipid Conjugates for Enhanced Oral Drug Delivery
    Tushar Date
    Kaushani Paul
    Navneet Singh
    Sanyog Jain
    AAPS PharmSciTech, 20
  • [4] TARGETED DRUG DELIVERY AND ADME OF ANTIBODY-DRUG CONJUGATES
    Alley, Stephen C.
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S9 - S9
  • [5] Development of lipoprotein-drug conjugates for targeted drug delivery
    Bhatia, Manish S.
    Choudhari, Sujata P.
    Dhavale, Rakesh P.
    Gaikwad, Vinod L.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (18): : 6955 - 6973
  • [6] Advances in the development of aptamer drug conjugates for targeted drug delivery
    Chen, Ke
    Liu, Bo
    Yu, Bo
    Zhong, Wen
    Lu, Yi
    Zhang, Jiani
    Liao, Jie
    Liu, Jun
    Pu, Ying
    Qiu, Liping
    Zhang, Liqin
    Liu, Huixia
    Tan, Weihong
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2017, 9 (03)
  • [7] Antibody-drug conjugates: targeted drug delivery for cancer
    Alley, Stephen C.
    Okeley, Nicole M.
    Senter, Peter D.
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (04) : 529 - 537
  • [8] Development of cholesterol-based conjugates for targeted drug delivery
    Alanazi, F
    Halpern, DS
    Lu, DR
    STP PHARMA SCIENCES, 2003, 13 (01): : 27 - 35
  • [9] Drug-Lipid Conjugates for Enhanced Oral Drug Delivery
    Date, Tushar
    Paul, Kaushani
    Singh, Navneet
    Jain, Sanyog
    AAPS PHARMSCITECH, 2019, 20 (02)
  • [10] NANOSTRUCTURED LIPID CARRIERS: A NOVEL TARGETED DRUG DELIVERY SYSTEM
    Patil, Deepak
    Pattewar, Seema
    Palival, Sarvesh
    Patil, Gargi
    Sharma, Swapnil
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (10): : 4784 - 4793